Stroke in patients with acute coronary syndromes. Incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial [PDF]
, 1999 BACKGROUND: The incidence of stroke in patients with acute coronary syndromes has not been clearly defined because few trials in this patient population have been large enough to provide stable estimates of stroke rates.
Alberts, MJ +15 more
core +6 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2017 BackgroundIn patients with non‐ST‐segment elevation acute coronary syndromes, inhibition of platelet aggregation (IPA) with a potent P2Y12 inhibitor, ticagrelor, was inferior to tirofiban infusion at 2 hours, indicating that glycoprotein IIb/IIIa ...
Moazez J. Marian +7 more
doaj +1 more source
The comparative safety of abciximab versus eptifibatide in patients on dialysis undergoing percutaneous coronary intervention: Insights from the Blue Cross Blue Shield of Michigan Cardiovascular Consortium (BMC2) [PDF]
, 2017 Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/138368/1/joic12388.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/138368/2/joic12388_am ...
Barnes +24 more
core +1 more source
Cryo-EM structures of full-length integrin αIIbβ3 in native lipids
Nature Communications, 2023 Platelet integrin αIIbβ3 is maintained in a bent inactive state (low affinity to physiologic ligand), but can rapidly switch to a ligand-competent (high-affinity) state in response to intracellular signals (“inside-out” activation).
Brian D. Adair +3 more
doaj +1 more source
Case Reports in Neurology, 2021 Acute ischemic vertebrobasilar stroke (AIVBS) is usually associated with poor outcome and prognosis and in case of basilar artery occlusion (BAO) with high mortality.
David Černík +3 more
doaj +1 more source
Co-administration of iloprost and eptifibatide in septic shock (CO-ILEPSS):A randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacyA randomised, controlled, double-blind investigator-initiated trial investigating safety and efficacy [PDF]
, 2019 Publisher's version (útgefin grein). The CO-ILEPSS trial was approved by the ethics committee in The Capital Region of Denmark with protocol number: H-3-2014-087.Background: Part of the pathophysiology in septic shock is a progressive activation of ...
Berthelsen, Rasmus Ehrenfried +3 more
core +2 more sources
Pharmaceutical Analysis of Eptifibatide via Simple, Rapid, Economical UV-Spectrophotometric Methods [PDF]
, 2015 Eptifibatide is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class. Pharmaceutically it is applied to reduce the risk of acute cardiac ischemic events.
Atul A. Shirkhedkar +2 more
core +2 more sources
Рациональная фармакотерапия в кардиологии, 2015 Clinical case history of endovascular intervention in infarct related coronary artery with 4 sirolimus-eluting stents implantation and their further thrombosis during early postoperative period is described.
K. A. Kireev +2 more
doaj +1 more source
Investigation of interaction of human platelet membrane components with anticoagulant drugs Abciximab and Eptifibatide. [PDF]
, 2011 Abciximab (Abci) and eptifibatide (Epti) are antiaggregate drugs which may reduce thrombotic complications in acute coronary syndromes. The aim of this work was the investigation of the interaction between the phospholipid-GPIIb/IIIa glycoprotein complex
Figaszewski, Zbigniew A +2 more
core +2 more sources
Eptifibatide in Coronary Intervention [PDF]
Circulation: Cardiovascular Interventions, 2015 Although percutaneous transluminal coronary intervention has revolutionized the management of patients with coronary artery disease, this technologic advance is neither innocuous nor a panacea. In addition to the technical limitations of the procedure, it is now well recognized that serious vascular injury is caused by the treatment device, which ...
Matthew W. Sherwood, James E. Tcheng
openaire +3 more sources